HIV Treatment Strategies
Author:
- Roy M. GulickRGRoy M. Gulick
- 25 March 1998
- journal article
- editorial
- Published by American Medical Association (AMA)
- Vol. 279 (12) , 957-959
Abstract
Significant progress has been made in the development of effective antiretroviral drug regimens for the treatment of human immunodeficiency virus (HIV) disease. Combinations of antiretroviral agents have been shown to decrease HIV RNA levels to the limit of detection of current viral load assays in a majority of patients for periods of months to years. These profound reductions in viral load reflect significant decreases in viral replication and appear to limit the emergence of resistant viral phenotypes, thereby promoting durable antiretroviral responses.Keywords
This publication has 12 references indexed in Scilit:
- The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirAIDS, 1998
- Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma ViremiaScience, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel1997
- Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266AIDS, 1996
- Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 InfectionAnnals of Internal Medicine, 1996
- L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1995
- Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitorsAntimicrobial Agents and Chemotherapy, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995